Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott Japan and Eisai have obtained Japanese marketing approval for their pancreatic digestive enzyme replacement drug Lipacreon (pancrelipase).
Subscribe to our email newsletter
Lipacreon is indicated as a treatment for pancreatic exocrine insufficiency (PEI) due to chronic pancreatitis, pancreatectomy, cystic fibrosis and other conditions.
Lipacreon contains pancreatic enzymes such as amylase, lipase and protease, which have been extracted and purified from porcine pancreas.
The results from a placebo-controlled double-blind trial in patients with PEI due to chronic pancreatitis or pancreatectomy, showed improvement as compared with placebo in fat absorption before and after the administration of Lipacreon as calculated from the volume of fat intake and the volume of fat in the patients’ stools.